N-Cadherin Antagonists as Oncology Therapeutics

Philosophical Transactions of the Royal Society B: Biological Sciences - United Kingdom
doi 10.1098/rstb.2014.0039
Full Text
Abstract

Available in full text

Date
Authors
Publisher

The Royal Society

Related search

The Future of Oncology Therapeutics

Expert Review of Anticancer Therapy
OncologyPharmacology
2017English

Dopamine D3 Receptor Antagonists as Potential Therapeutics for the Treatment of Neurological Diseases

Frontiers in Neuroscience
Neuroscience
2016English

Molecular Biology and Therapeutics in Musculoskeletal Oncology*

Journal of Bone and Joint Surgery - Series A
MedicineSurgeryOrthopedicsSports MedicineSports Science
2009English

N-Cadherin Relocalization During Cardiac Trabeculation

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2016English

Berichtigung: Engineered Substrate-Specific Delta PKC Antagonists to Enhance Cardiac Therapeutics

Angewandte Chemie
2017English

Cannabinoids as Therapeutics

2005English

Biomimetic Particles as Therapeutics

Trends in Biotechnology
BioengineeringBiotechnology
2015English

Differential Expression of N-Cadherin and E-Cadherin in Normal Human Tissues

Archives of Histology and Cytology
Histology
2006English

Ribonuclease as Anticancer Therapeutics

Enzyme Engineering
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy